The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index; 7 of the 105 sources its claims cite were checked for support.
From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management
Open accessAbstract
Aims. Despite the very clear association between polycystic ovary syndrome (PCOS) and dysglycemia, few studies have explored the continuum of glycemic alterations leading from minor glucose abnormalities to overt diabetes. The purpose of this review is to trace the natural history of glycemic alteration in women with PCOS.Methods. We performed a literature review without time limit until August 2019. Inclusion criteria were studies addressing the association between impaired glucose tolerance or impaired fasting glucose or type 2 diabetes (T2D) and PCOS with at least an English abstract. The exclusion criteria were no PCOS or impaired glucose tolerance or impaired fasting glucose or T2D as outcome. The outcomes of interest were the onset of impaired glucose tolerance, impaired fasting glucose, T2D, and the progression from impaired glucose tolerance or impaired fasting glucose to T2D.Results. Healthy diet and physical activity are the first-line therapy for PCOS. Treatment with metformin was associated with significant lower 2-hour postload glucose levels and with reduction in fasting glucose when compared to placebo. Thiazolidinediones were more effective in reducing fasting glucose levels compared to placebo. Metformin and pioglitazone treatments showed similar effects on fasting glucose levels. The sodium-glucose cotransporter-2 inhibitor empagliflozin did not show differences in metabolic parameters when compared to metformin. The combination therapy with metformin plus the glucagon-like peptide-1 receptor agonist liraglutide was associated with significant improvements in basal and postload glucose levels compared with only liraglutide. Likewise, a combination therapy with the dipeptidyl peptidase-4 inhibitor saxagliptin and metformin demonstrated superiority versus metformin in fasting glucose and oral glucose tolerance test normalization. Myo-inositol supplementation was associated with lower insulin levels, glucose levels, and insulin resistance when compared with placebo, metformin, or estrogen treatments.Conclusions. The use of insulin-sensitizing agents, such as metformin and inositols, along with lifestyle interventions may improve the metabolic profile in PCOS women.
Overview
CoChat Summary
TL;DR
This narrative review traces the continuum of glycemic alterations in women with polycystic ovary syndrome (PCOS), from impaired glucose tolerance and impaired fasting glucose to type 2 diabetes, and summarizes lifestyle and pharmacological management options. It concludes that insulin-sensitizing agents such as metformin and inositols, combined with lifestyle intervention, may improve the metabolic profile in PCOS women.
Key findings
- PCOS is associated with a two times increased risk for type 2 diabetes; impaired glucose tolerance prevalence is almost 30% in both adult women and affected adolescents, and insulin action is reduced by 35–40% in lean and obese women with PCOS versus controls.
- Lifestyle modification (diet and physical activity) is the first-line therapy; for overweight women, lowering body mass by 5% can reduce serum insulin and testosterone levels and improve menstrual and reproductive function.
- Metformin was associated with lower fasting glucose versus placebo or no treatment (MD −0.14 mmol/L; 95% CI −0.21 to −0.07) in one Cochrane meta-analysis, though a second meta-analysis of 13 RCTs and 506 subjects found no impact (MD −1.38 mmol/L; 95% CI −3.71, 0.94). In obese adolescents with PCOS and IGT, 8 of 15 normalized their OGTT (2-hour glucose 9.1 ± 0.3 vs. 7.4 ± 0.3 mmol/l; p = 0.005).
- Thiazolidinediones were more effective than placebo in reducing fasting glucose (MD −0.55 mmol/l; 95% CI −1.06 to −0.05; p = 0.031) and showed similar effects to metformin (MD 0.21 mmol/l; 95% CI −0.46 to 0.03; p = 0.089). In one pioglitazone trial, 40% of patients with altered OGTT reverted to normality versus none in the placebo arm.
- Empagliflozin showed no differences in metabolic parameters versus metformin, but favorable effects on body weight (−1.4 kg ± 3.2% vs. 1.2 kg ± 2.3%; p = 0.006) and BMI (p = 0.006). Metformin plus liraglutide improved OGTT at 0 and 120 min versus liraglutide alone (p = 0.015); saxagliptin plus metformin was superior to metformin for fasting glucose and OGTT normalization (p = 0.007), with 91% normalization in the combination arm.
- Myo-inositol improved insulin resistance (HOMA index WMD −1.11; 95% CI −1.39–0.83; p < 0.00001 vs. placebo) and fasting insulin (WMD −3.97; 95% CI −5.76, −2.18; p < 0.00001 vs. placebo), though evidence for an effect on fasting glucose was not strong.
Methods
- Literature review without time limit until August 2019, searching PubMed/Medline, Scopus, Web of Science, Science Direct, Embase, CINAHL, EBSCO, and Google Scholar using MeSH keywords for IGT, IFG, T2D, and PCOS.
- Inclusion criteria: studies addressing the association between IGT, IFG, or T2D and PCOS with at least an English abstract, with focus on available PCOS treatment; exclusion criteria: no PCOS/IGT/IFG/T2D as outcome, conference presentations, and letters to editors.
- All steps independently performed by two researchers, with disagreements resolved by a third researcher; outcomes of interest were onset of IGT, IFG, T2D, and progression from IGT/IFG to T2D.
Limitations
- As stated by the authors: in most PCOS treatment trials the primary objectives are hormonal parameters, ovulatory function, or menstrual irregularities, so studies were underpowered to detect changes in metabolic parameters or diabetes prevention as secondary outcomes; very few studies analyze prediabetes treatment in PCOS and some are retrospective; most have small sample sizes and short observation times (not exceeding 24 weeks for longer studies).
- Evident from the text: the review is narrative rather than systematic, with no formal risk-of-bias assessment or quantitative synthesis; several cited findings are drawn from single small trials or pilot studies (e.g., the 20-subject inositol T2D pilot, the 40-patient empagliflozin RCT), and the authors note that studies analyzing preventive effects from T2D in PCOS women are still lacking.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
7 Valid · 1 Not valid · 70 Not checked · 18 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“High intensity aerobic exercise with heart rate >80% improves IR in women with PCOS [38].”
§ From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management > 3. Results and Discussion > 3.2. Lifestyle Modifications
What the sources say
- Partly supportedcites [38] sourceExperimental — accuracy not yet measured
The Exercise Intervention Effects section reports a 16% improvement in insulin resistance among women with PCOS after exercise. The Exercise Intervention section describes a program alternating moderate- and high-intensity sessions, but our copy does not establish that the high-intensity sessions used a heart-rate threshold above 80%; its reference to >80% concerns VO₂max, not heart rate. The study also involved overweight and obese women with PCOS, rather than women with PCOS generally. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Women with PCOS have a higher cardiometabolic risk compared with women without ovarian problems [11].”
§ From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management > 1. Introduction
What the sources say
- Supportedcites [11] source
The Introduction identifies PCOS as a leading risk factor for dysglycemia and type 2 diabetes, and the Cardiovascular Disease Risk Factors section reports increased cardiovascular risk markers in some studies compared with reproductively normal women. This supports the broad claim about cardiometabolic risk; the review distinguishes those risk markers from cardiovascular events, for which increased risk remains uncertain. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The arm with saxagliptin plus metformin demonstrated superiority versus metformin in fasting glucose and OGTT normalization (p = 0.007).”
§ From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management > 3. Results and Discussion > 3.7. GLP-1 Receptor Agonist and DPP4 Inhibitors
What the sources say
- Partly supportedcites [69] sourceExperimental — accuracy not yet measured
The Results (Table 2; page unavailable) show that fasting glucose and two-hour OGTT glucose improved in both the combination and metformin groups. They do not report OGTT normalization rates or a superiority comparison for these outcomes at p = 0.007; the reported between-group advantage concerns HbA1c (Abstract, Results). (LLM, conf=0.85)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“When comparing metformin plus OCP to OCP alone, a better outcome on fasting glucose has been shown by Teede et al. [50] in favour of metformin plus OCP (MD 0.38 mmol/l; 95% CI0.22 to 0.54).”
§ From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management > 3. Results and Discussion > 3.3. Metformin
What the sources say
- Supportedcites [50] source
Section 3.7 (p. 6) reports a statistically significant improvement in fasting glucose with COCP plus metformin versus COCP alone in adults with PCOS. The reported difference is 0.38 mmol/L (95% CI 0.22 to 0.54), matching the claim. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“After 12 weeks of treatment, the authors observed a significant improvement in the OGTT at 0 and 120 min in the combination therapy arm (p = 0.015).”
§ From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management > 3. Results and Discussion > 3.7. GLP-1 Receptor Agonist and DPP4 Inhibitors
What the sources say
- Partly supportedcites [68] sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a causen = 30 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
56 more claims · 2 with their cited sources checked
Create a free account to see all 96 claims and to verify the 98 references still open.
- Probably not a substantial claim. 5
- It may state two separate claims as one. 30
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, hyperinsulinemia is responsible for the increase in the androgen production through both the direct stimulation of insulin receptors and the cross-reaction with Insulin-like Growth Factor-1 (IGF-1) receptors expressed on thecal cells [14].”
From Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? (2023) · cites this paper as [14]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management > 3. Results and Discussion > 3.5. Thiazolidinediones
“patients treated with placebo had a deterioration of the glucose tolerance measured at the OGTT with respect to the group treated with placebo.”
§ From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management > 3. Results and Discussion > 3.5. Thiazolidinediones
“13 women with PCOS treated for 6 months with pioglitazone 45 mg per day with 10 women treated with placebo.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management > 3. Results and Discussion > 3.5. Thiazolidinediones
“MD: 0.21 mmol/l”
§ From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management > 3. Results and Discussion > 3.5. Thiazolidinediones
“95% CI −0.46 to 0.03”
Citations
Cites
1 retracted
Psychological interventions for overweight or obesity
Shaw, K. A., O'Rourke, P., Del Mar, C., & Kenardy, J. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003818.pub2 · Cited by 442
RetractedGlucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967
Diamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947
Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., & the International PCOS Network (2018) · Clinical Endocrinology · doi:10.1111/cen.13795 · Cited by 1,823
Legro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743
Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., Andersen, M., Azziz, R., et al. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.05.004 · Cited by 1,325
Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
Madiraju, A. K., Erion, D. M., Rahimi, Y., Zhang, X.-M., Braddock, D. T., Albright, R. A., Prigaro, B. J., Wood, J. L., Bhanot, S., MacDonald, M. J., et al. (2014) · Nature · doi:10.1038/nature13270 · Cited by 1,284
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.141 · Cited by 1,257
Research works printed but not linked: 2
- 2018, European Review for Medical and Pharmacological Sciences, 22, 6567
- 2012, European Review for Medical and Pharmacological Sciences, 16, 575
Cited by
Polycystic ovary syndrome and type 2 diabetes mellitus: A state-of-the-art review
Livadas, S., Anagnostis, P. G., Bosdou, J. Κ., Bantouna, D., & Paparodis, R. D. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i1.5 · Cited by 129
PCOS and nutritional approaches: Differences between lean and obese phenotype
Barrea, L., Frias-Toral, E., Verde, L., Ceriani, F., Cucalón, G., Garcia-Velasquez, E., Moretti, D., Savastano, S., Colao, A., & Muscogiuri, G. (2021) · Metabolism Open · doi:10.1016/j.metop.2021.100123 · Cited by 86
Shpakov, A. O. (2021) · Pharmaceuticals · doi:10.3390/ph14010042 · Cited by 91
Role of macrophages in the endocrine system
Rehman, A., Pacher, P., & Haskó, G. (2021) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.12.001 · Cited by 71
Research Progress on the Mechanism Between Polycystic Ovary Syndrome and Abnormal Endometrium
Xue, Z., Li, J., Feng, J., Han, H., Zhao, J., Zhang, J., Han, Y., Wu, X., & Zhang, Y. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.788772 · Cited by 64
Metadata
- Authors
- Pani, A., Gironi, I., Di Vieste, G., Mion, E., Bertuzzi, F., & Pintaudi, B.
- Affiliations
- University of Milan (IT)
- Diabetes Consultant, Milan, Italy
- Diabetes Unit, Cantù Hospital, Abbiategrasso, Italy
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Corresponding author
- Pintaudi, Basilio
- Venue
- International Journal of Endocrinology
- Publisher
- Wiley
- Published
- 2020-06-08
- Volume
- 2020
- Pages
- 1-10
- ISSN
- 1687-8337 (ISSN-L)
- 1687-8345
- PMC
- PMC7298266
- OpenAlex
- W3034163622
- Semantic Scholar
- 7587392706ddd7085ef3c29f2dcc1a4bdb0e0876
- Cited by
- 38
- References
- 91
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 4 · 2023: 9 · 2022: 8 · 2021: 6 · 2020: 3
- FWCI
- 0.96
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- International Journal of Endocrinology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- polycystic ovary syndrome, type 2 diabetes, prediabetes, impaired glucose tolerance, impaired fasting glucose, dysglycemia, metformin, thiazolidinediones, pioglitazone, empagliflozin, liraglutide, saxagliptin, myo-inositol, insulin resistance, lifestyle intervention, physical activity, diet, insulin sensitizers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management. https://app.cochat.ai/papers/10.1155/2020/6276187
- The paper
- Pani, A., Gironi, I., Di Vieste, G., Mion, E., Bertuzzi, F., & Pintaudi, B. (2020). From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management. International Journal of Endocrinology. https://doi.org/10.1155/2020/6276187
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.